These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12867061)

  • 21. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
    Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
    Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
    Collins DM; Crown J; O'Donovan N; Devery A; O'Sullivan F; O'Driscoll L; Clynes M; O'Connor R
    Invest New Drugs; 2010 Aug; 28(4):433-44. PubMed ID: 19499189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.
    Raben D; Helfrich B; Ciardiello F; Bunn PA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S15-22. PubMed ID: 12867058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA; Kolesar JM
    Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 33. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
    Chou LS; Garey J; Oishi K; Kim E
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
    Majem M; Pallarès C
    Clin Transl Oncol; 2013 May; 15(5):343-57. PubMed ID: 23359171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
    Bunn PA
    J Clin Oncol; 2007 Jun; 25(18):2504-5. PubMed ID: 17577025
    [No Abstract]   [Full Text] [Related]  

  • 40. EGFR inhibitors: clinical results.
    De Marinis F; Nelli F; D'Auria G
    Suppl Tumori; 2002; 1(6):S5-6. PubMed ID: 12658893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.